Ondo data two Coronavirus deaths

Ondo state has recorded two new deaths linked to Coronavirus problems. The state’s Governor, Rotimi Akeredolu confirmed this in a tweet shared on Monday June 1.


Akeredolu mentioned the 2 late Coronavirus sufferers are among the many three new instances reported within the state. They died at the College of Medical Sciences Educating Hospital (UNIMEDTH) in Ondo city, Ondo State.


This brings the entire variety of Coronavirus deaths recorded within the South-West state to 4. The tweet reads;


At the moment, we recorded three new instances and an unprecedented variety of deaths from #COVID19Nigeria in Ondo State. Two of the brand new instances handed on at UNIMED in Ondo city this morning. The third case is presently on the IDH in Akure present process remedy.


Ondo records two Coronavirus deaths


276 new cases of COVID-19 recorded in Nigeria

276 new cases of COVID-19 were recorded in Nigeria on Tuesday, May 26, 2020.

According to the Nigeria Center for Disease Control (NCDC), 161 cases were recorded in Lagos, 36 in Rivers, 27 in Edo, 19 -Kaduna, 10 in Nasarawa, 6 in Oyo-, 4 in Kano, 3 in Delta, 3 in Ebonyi, 2 in Gombe, 1 in Ogun, 1 in Ondo, 1 in Borno, 1 in Abia, and 1 in Bauchi State.

In total, Nigeria has now recorded 8344 cases of COVID-19. 2385 patients have been discharged from various Isolation centers across the country, while 249 deaths have been recorded.

276 new cases of COVID-19 recorded in Nigeria


245 new cases of COVID-19 recorded in Nigeria

245  new circumstances of COVID-19 had been recorded in Nigeria on Friday, Might 22, 2020.


In line with the Nigeria Heart for Illness Management NCDC, 131 circumstances had been recorded in Lagos, 16 in Jigawa, 13 in Ogun, 12 in Borno, 9 in Kaduna, 9 in Oyo, 9 in Rivers, 9 in Ebonyi, eight in Kano, 7 in Kwara, 5 in Katsina, three in Akwa Ibom, three in Sokoto, 2 in Bauchi, 2 in Yobe, 1 in Anambra, 1 in Gombe, 1 in Niger, 1 in Ondo, 1-Plateau, 1-FCT, 1 in Bayelsa State.

In complete, Nigeria has recorded 7261 circumstances of COVID-19. 2007 sufferers have been discharged from varied Isolation facilities throughout the nation, whereas 221 deaths have been recorded.

245 new cases of COVID-19 ?recorded in Nigeria


245 new circumstances of COVID-19 recorded in Nigeria

245  new circumstances of COVID-19 have been recorded in Nigeria on Friday, Might 22, 2020.


Based on the Nigeria Middle for Illness Management NCDC, 131 circumstances have been recorded in Lagos, 16 in Jigawa, 13 in Ogun, 12 in Borno, 9 in Kaduna, 9 in Oyo, 9 in Rivers, 9 in Ebonyi, eight in Kano, 7 in Kwara, 5 in Katsina, three in Akwa Ibom, three in Sokoto, 2 in Bauchi, 2 in Yobe, 1 in Anambra, 1 in Gombe, 1 in Niger, 1 in Ondo, 1-Plateau, 1-FCT, 1 in Bayelsa State.

In whole, Nigeria has recorded 7261 circumstances of COVID-19. 2007 sufferers have been discharged from numerous Isolation facilities throughout the nation, whereas 221 deaths have been recorded.

245 new cases of COVID-19 ?recorded in Nigeria


Covid-19: we don’t know the whereabout of the Chinese-FG

Terrifying experiment exhibits how rapidly Coronavirus can unfold in eating places inside minutes (Video)

The federal Government has said it does not know the whereabout and technicians who came into the country to offer assistance to Nigeria in the fight against the Coronavirus Pandemic.

180nobs gathered that after speaking at the daily briefing of Health of the PTF in Abuja on Thursday, the minister of Health, Dr. Ossagie Ehanire wondered why there was so much interest in knowing their whereabout and he told journalists not to ask him question again.

Ehanire said: “I want to explain first of all that I think not all of them were doctors and I heard that some of them are technicians, but thy are staff of CCECC, the ministry of health is not their host, so we can’t always explain what happened to them or where they are.

There seems to be a lot of interest in these doctors but they are the staff of company and I think they are on the company Visa.

So, I will be very happy if you don’t ask me about where they are because they are not really our guests in that sense.

But we have been able to learn somethings from them which was very interesting from their Country, we shared ideas about what they do in their Country in managing Covid-19.”


Edo state data yet one more COVID-19 demise, discharges 20 sufferers

Edo state records one more COVID-19 death, discharges 20 patients


The Coronavirus pandemic has claimed the lifetime of one other affected person within the Edo state Isolation heart.


The state governor, Godwin Obaseki, introduced this at the moment Might 14. This brings to 5 the variety of COVID-19 associated deaths recorded within the state.


In a associated improvement, 20 COVID-19 sufferers had been discharged from the Isolation heart within the state at the moment after they examined destructive for the virus.

 “We now have discharged 20 individuals from our COVID-19 isolation amenities. 17 are from Stella Obasanjo Hospital; one from College of Benin Educating Hospital and two others from Irrua Specialist Educating Hospital.
To date, 34 individuals have been discharged. A affected person, who reported late for therapy, was misplaced to the virus. Keep secure.” he tweeted

Edo state records one more COVID-19 death, discharges 20 patients

Source: Lindaikejisblog


98-year-old lady recovers from Coronavirus in Lagos

98-year-old woman recovers from Coronavirus in Lagos


A 98-year-old lady was reportedly discharged in Lagos at present Might 13, after recovering from Coronavirus.


A physician who shared the story on Twitter, mentioned the aged affected person was discharged from Eti-Osa Isolation Middle.


@drbellanifemi tweeted;


The Pleasure at our Eti-Osa Isolation Middle at present is indescribable. We simply discharged our oldest affected person, a 98 yr outdated lady. So glad she’s going residence hale and hearty. Can’t submit photos and movies as a result of we weren’t given consent.

I truly hav some movies n photos of ppl that gave me consent to submit them. I jst wish to edit dem, blurr their faces due to d mentality of some Nigerians. I don’t need any stigmatization for them in future. I can’t edit n I don’t know who I can belief wit it #CovidIsReal


98-year-old woman recovers from Coronavirus in Lagos98-year-old woman recovers from Coronavirus in Lagos

Source: https://bit.ly/3bz6m26


Important -Pharmacist dies after drinking chemical concoction he developed.

Unbelievable- Pharmacist dies after drinking chemical concoction he developed

Pharmacist dies

Pharmacist dies

Shocking as An Indian pharmacist was confirmed dead on Saturday May 9, after he drank a chemical concoction he developed in a bid to treat Coronavirus.


47-year-old K. Sivanesan who worked with Chennai-based Sujatha Biotech, an Ayurvedic and herbal products company which was founded 30 years ago, died on the spot while his colleague, a managing director of the company who is an ophthamologist by qualification, was hospitalised after he fainted soon after he ingested the chemical component.


The two men reportedly ingested the chemical mixture of nitric oxide and sodium nitrate at a home in southern Chennai city.

Deputy Commissioner of Police,Ashok Kumar said;

“Our investigation revealed that Sivanesan died after drinking the preparation he claimed would help COVID-19 patients. His managing director fainted after tasting it initially. Further investigation is on.”

N.S.Vasan, designer-cum-media manager of the company said;

“Due to the lockdown, Sivanesan stayed in the city and one day told us he heard of some medicine from U.S. President Donald Trump’s recent speech for curing Coronavirus. He said it would bring more immunity and help to prevent COVID-19. Deciding to test the effect of the medicine, he went to Parry’s Corner and bought the powder. Sivanesan must have taken a heavy dosage of the ‘drug’ and he was killed instantly.

 “All our products are ayurvedic. We used to test only herbal products. This was a chemical product that Sivanesan was testing though, and possibly for the first time ever.”

India currently has nearly 60,000 confirmed cases of Coronavirus. There are no approved medicines or vaccines for treating COVID-19, triggering a global race for a new drug for the disease that has killed 277,946 worldwide.

Source: https://bit.ly/2SSgEUq

Continue Reading


Pfizer and BioNTech Dose First Participants in the U.S as Part of COVID-19

Pfizer and BioNTech Dose First Participants in the U.S as Part of Global COVID-19 mRNA Vaccine Development Program

First participants dosed at NYU Grossman School of Medicine and University of Maryland School of Medicine

Pfizer and BioNTech ramping up manufacturing capabilities to further increase production capacity in 2020/2021

(NEW YORK, USA, and MAINZ, Germany, May 5, 2020)Pfizer Inc. (NYSE:PFE) and BioNTech SE (Nasdaq: BNTX) announced on Wednesday, May 6, 2020 that the first participants have been dosed in the U.S in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week.

The Phase 1/2 study is designed to determine the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates evaluated in a single, continuous study. The dose level escalation portion (Stage 1) of the Phase 1/2 trial in the U.S will enroll up to 360 healthy subjects into two age cohorts (18-55 and 65-85 years of age). The first subjects immunized in Stage 1 of the study will be healthy adults 18-55 years of age. Older adults will only be immunized with a given dose level of a vaccine candidate once testing of that candidate and dose level in younger adults has provided initial evidence of safety and immunogenicity. Sites currently dosing participants include NYU Grossman School of

Medicine and the University of Maryland School of Medicine, with the University of Rochester Medical Center/Rochester Regional Health and Cincinnati Children’s Hospital Medical Center to begin enrollment shortly.

“With our unique and robust clinical study program underway, starting in Europe and now the U.S., we look forward to advancing quickly and collaboratively with our partners at BioNTech and regulatory authorities to bring a safe and efficacious vaccine to the patients who need it most. The short, less than four-month timeframe in which we’ve been able to move from pre-clinical studies to human testing is extraordinary and further demonstrates our commitment to dedicating our best-in-class resources, from the lab to manufacturing and beyond, in the battle against COVID-19,” said Albert Bourla, Chairman and CEO, Pfizer.

Pfizer and BioNTech’s development program includes four vaccine candidates, each representing a different combination of mRNA format and target antigen. The novel design of the trial allows for the evaluation of the various mRNA candidates simultaneously in order to identify the safest and potentially most efficacious candidate in a greater number of volunteers, in a manner that will facilitate the sharing of data with regulatory authorities in real time.

“It is encouraging that we have been able to leverage more than a decade of experience in developing our mRNA platforms to initiate a global clinical trial in multiple regions for our vaccine program in such a short period. We are optimistic that advancing multiple vaccine candidates into human trials will allow us to identify the safest, most effective vaccination options against COVID-19,” said CEO and Co-founder of BioNTech, Ugur Sahin.

During the clinical development stage, BioNTech will provide clinical supply of the vaccine from its GMP-certified mRNA manufacturing facilities in Europe.  In anticipation of a successful clinical development program, Pfizer and BioNTech are working to scale up production for global supply.


Pfizer plans to activate its extensive manufacturing network and invest at risk in an effort to produce an approved COVID-19 vaccine as quickly as possible for those most in need around the world. The breadth of this program should allow production of millions of vaccine doses in 2020, increasing to hundreds of millions in 2021. Pfizer-owned sites in three U.S. states (Massachusetts, Michigan and Missouri) and Puurs, Belgium have been identified as manufacturing centers for COVID-19 vaccine production, with more sites to be selected. Through its existing mRNA production sites in Mainz and Idar-Oberstein, Germany, BioNTech plans to ramp up its production capacity to provide further capacities for a global supply of the potential vaccine.

BioNTech and Pfizer will work jointly to commercialize the vaccine worldwide upon regulatory approval (excluding China, where BioNTech has a collaboration with FosunPharma for BNT162 for both clinical development and commercialization).


Covid-19 Update in Nigeria

The spread of novel Corona Virus Disease (COVID-19) in Nigeria has continued to record rapid increase as the latest statistics provided by the Nigeria Centre for Disease Control showed that there are 2,802 confirmed cases.

On the 4th of May 2020, 245 new confirmed cases and 6 deaths were recorded in Nigeria

ll date, 2802 cases have been confirmed, 417 cases have been discharged and 93 deaths have been recorded in 34 states and the Federal Capital Territory.

The 245 new cases are reported from 16 states- Lagos(76), Katsina(37), Kano(23), FCT(19), Jigawa(32), Borno(18), Edo(10), Bauchi(9), Adamawa(6) Oyo(5), Ogun(5), Ekiti(1), Osun(1), Benue(1), Niger(1), Zamfara(1).


In a move to combat the spread of the pandemic disease, President Muhammadu Buhari directed the cessation of all movements in Lagos and the FCT for an initial period of 14 days, which took effect from 11 pm on Monday, 30th March 2020.

The movement restriction, which was extended by another two-weeks period, has been partially put on hold with some businesses commencing operations from May 4.

The latest numbers bring Lagos state total confirmed cases to 1183, followed by Kano (365), Abuja at 297, Borno (100), Gombe (96) Ogun (85), Katsina (83), Kaduna (81),  Bauchi (80),  Sokoto (66),  Edo (62), Oyo and Jigawa (39), Osun (37),  Delta (17), Akwa Ibom and Kwara (16), Rivers (14), Yobe, Zamfara, and Ondo (13), Ekiti, Adamawa, and Kebbi (12), Nasarawa (11), Taraba and Enugu (8),  Bayelsa and Ebonyi (5),  Niger (4), Plateau (3), Abia, Benue, and Imo (2), while Anambra state recorded one case.


Is this a solution?COVID-19: FG to disinfect schools nationwide

COVID-19: FG to disinfect schools nationwide

The Federal Government has announced plans for the disinfection and decontamination of schools nationwide.


Muhammad Mahmood, the Minister of Environment disclosed this at the Presidential Task Force briefing on COVID-19 in Abuja.


He said the Federal Ministry of Environment would get the data of schools nationwide from the Federal Ministry of Education before commencing.


Mahmood said, “We are initiating a programme of decontaminating and disinfecting our schools before they open.


“Because subsequently in the phases (of reopening the lockdown), I believe we will get to that point when we start opening the schools.


“So, we will be liaising with the Federal Ministry of Education to make sure we have the needed data to carry out the exercise.”


He also noted that ministry had been making efforts to commence the programme, but didn’t state when the exercise would start.


Mahmood said, “Today we will like to brief you on our first video conference with our Environmental Health Sanitation desks across the country, the 36 states plus the FCT.


“Also in attendance was a representative of the World Health Organisation, the purpose of which is to build additional capacity and to reiterate adherence to the guidelines in this response to COVID-19.”


Covid-19 killed mother and son in Osun

Mother And Son Test Positive For COVID-19 In Osun

Osun State has recorded two new coronavirus cases as wife and son of patient who died of the virus tested positive bringing the toll of the state to 36.

The Chief Press Secretary to the governor, Mr. Ismail Omipidan, disclosed this in a statement on Sunday.

He noted that the Commissioner of Health, Dr. Rafiu Isamotu, said two new cases were confirmed by the Nigeria Centre for Disease Control, NCDC last night.

His words: “Last night, we received results of 53 samples we sent to the NCDC accredited Testing Centre for evaluation, out of which 2 tested positive and 51 returned negative.

“The two positive cases are wife and son of a previously confirmed case in Ife, who died last week. They are currently receiving treatment at our Isolation Centre,” he said.

Isamotu further revealed that with the development, Osun now has 36 confirmed cases, ten active cases.

Source:- TheNationOnline


Pope Francis- Coronavirus vaccine must be shared worldwide

Leader of the Roman Catholic Church, Pope Francis, has called for international scientific cooperation so that every country of the world will benefit from a Coronavirus vaccine when it is made.
The Pope who was speaking from the papal library at the Vatican while delivering his Sunday service address today, said any successful vaccine developed should be made available around the world to benefit all of humanity.

Pope Francis also thanked all those around the world, providing essential services.

“In fact, it is important to unite scientific capabilities, in a transparent and impartial way to find vaccines and treatments,” he said.

”It is also important to guarantee universal access to essential technologies that allow each infected person, in every part of the world, to receive the necessary medical treatment.”
Recall that World leaders pledged in April to accelerate work on tests, drugs and vaccines against the disease and share their findings, but the United States did not take part in the launch of the World Health Organization (WHO) initiative after Trump announced he was halting funds to the WHO over what his administration feels was the agency’s pandering to China.


Coronavirus has infected nearly 3.5 million people and killed more than 240,000 people worldwide.


Nasarawa state government sends 788 Almajiris back to their homestates amid Covid-19 pandemic

Nasarawa state government sends 788 Almajiris back to their homestates amid Coronavirus pandemic

The Nasarawa state government has sent 788 almajiris back to their various home states today Sunday May 3.


This move comes amid efforts by the state government to stop the spread of the novel Coronavirus in the state.


The state governor, Abdullahi Sule, who supervised the deportation of the first batch of the Almajiris, said the decision is in good faith and with no bad motive. He added that the Almajiris were being sent back so their parents can take better care of them.


Nasarawa state government sends 788 Almajiris back to their homestates amid Coronavirus pandemicNasarawa state government sends 788 Almajiris back to their homestates amid Coronavirus pandemicNasarawa state government sends 788 Almajiris back to their homestates amid Coronavirus pandemicNasarawa state government sends 788 Almajiris back to their homestates amid Coronavirus pandemic


Covid-19 Doctors in Ogun to embark on three-days warning strike

Resident doctors at the Olabisi Onabanjo University Teaching Hospital, Sagamu, Ogun State, says they will be embarking on a three-day warning strike starting from on Monday May 4th.


In a letter jointly signed by the President and General Secretary of the Association, Popoola Mutiua and Osundara Tope, respectively, the doctors said they decided to embark on strike to demand for appropriate remuneration for doctors in OOUTH as they battle the COVID-19 pandemic.


The aggrieved doctors say the association would review the response of the government after the three-day warning strike.


The letter in part reads


“We have a human face and we know people are the basis of our practice as medical professionals. We shall, therefore, exclude our members working at COVID-19 isolation centre from joining the strike action. They shall not take part in the strike. Following the three-day warning strike, we shall review the government’s response and appropriate action shall be taken thereafter.

The whole house is very much displeased with the government on issues that bother on our agitations and welfare. We are perturbed with the non-committal response from the government despite repeated calls and letters to get their attention.

There has been no commitment whatsoever from the government on the issue of Appropriate Remuneration, Entry Level, New Minimum Wage, Hazard allowance and Life Insurance for our members. No response to the letter written by the National Body of the Association of Resident Doctors notifying Ogun State Government on the aberration concerning the Appropriate Remuneration to her members at OOUTH.

Despite the inadequate response of Ogun State Government to the Health risks confronted by our members during this COVID-19 pandemic, our members went ahead to continue their work diligently in their various departments and at the Isolation Centre. We were taken aback by the arbitrary change in only hazard allowance to be given as COVID-19 Special Hazard Allowance to all health workers. The 200 per cent increase in hazard allowance is just an increase from N5000 to N15,000 for just the month of April.”


Anambra State Bans Preservation Of Corpses In Mortuaries Due To Coronavirus

As part of measures to contain the spread of Coronavirus in the state, the Government of Anambra State has presently outlawed preservation of bodies in morgues.

In a statement, Thursday, Secretary to the State Government, Prof. Solo Chukwulobelu, directed that families across the state should bury their loved ones as soon as the death occurs.

It said that the burial should not involve more than 30 persons during which the guidelines on social distancing and wearing of face masks must be strictly observed.

“The governor of Anambra State, Chief Willie Obiano, has directed that families across the state should bury their loved ones as soon as the death occurs.

The burial should not involve more than 30 persons during which the guidelines on social distancing and wearing of face masks must be strictly observed.


New York state duped of $69million by man who tweeted at Trump claiming he could supply 1450 ventilators


New York state duped of $69million by man who tweeted at Trump claiming he could supply 1450 ventilators

A man who claims to be a Silicon Valley entrepreneur, with no experience or knowledge in government contracting or medical supplies, has reportedly duped New York state of $69million just by tweeting at US President Trump that he could supply 1450 ventilators to help the state of New York in it’s battle against Coronavirus.

Yaron Oren-Pines, who is actually an electrical engineer, was paid $47,656 each for 1,450 ventilators by New York state in March after he tweeted at Trump.


Trump posted a tweet on March 27 urging American companies to ‘START MAKING VENTILATORS, NOW!’


Oren-Pines, founder of networking solutions company Legasus Networks, then replied to Trump’s Tweet saying: ‘We can supply ICU Ventilators, invasive and noninvasive. Have someone call me URGENT.’


New York state duped of $69million by man who tweeted at Trump claiming he could supply 1450 ventilators


Over one month since he was paid the whooping sum of $69 million, New York state is yet to receive a single ventilator from him.

No word has been heard from the man as the US have now canceled his contract and are trying to get their money back.


New York state duped of $69million by man who tweeted at Trump claiming he could supply 1450 ventilators


Media agencies in the US don’t even know if the photo on the man’s twitter profile is actually that of Oren-Pines.


The price of the ventilators, $47,656 each for 1,450 ventilators, is almost times three of the actual price and the state say they paid the high amount out of desperation as they battled the Coronavirus pandemic and the toll it brought to the health system.


This isn’t the first inflated and suspicious contract the NY state government under Governor Andrew Cuomo (pictured below) has entered into since the Coronavirus outbreak in the state.
New York state duped of $69million by man who tweeted at Trump claiming he could supply 1450 ventilators


Dome International, a Brooklyn company, was given almost $116 million for 5,700 ventilators in two separate payments – which have also not been supplied


A New York state official speaking to Buzzfeed News said they awarded the contract to Oren-Pines based on White House advice.

‘The guy was recommended to us by the White House coronavirus task force because they were doing business with him as well,’ the official told Buzzfeed News.


Rich Azzopardi, a senior adviser to New York Governor Andrew Cuomo, told Buzzfeed the state paid the high costs because it was desperate to save the lives of New Yorkers.

‘We had no choice but to overturn every rock to find ventilators and other needed equipment,’ he said.

‘States were forced to fend for themselves to purchase lifesaving supplies to combat a global pandemic and with all modeling showing a more severe spread of this virus with more hospitalizations and more fatalities.’


babafemi taiwo is leading major study on drug remdesivir that appears to treat covid-19 video, cure to coronavirus, remdesivir, nigerian doctor in us, covid19

Nigerian doctor in US, Babafemi Taiwo is leading major study on drug Remdesivir that appears to treat COVID-19 (video)

A Nigerian doctor named Babafemi Taiwo is leading a major study on an antiviral drug named Remdesivir that appears to be effective in treating COVID-19.


CNN interviewed Dr Babafemi Taiwo to discuss the result of Remdesivir in treating Coronavirus.


Preliminary results of Remdesivir show it can help hospitalized COVID-19 patients recover faster.


Though Remdesivir, an antiviral drug made by Gilead Sciences, appears to help patients with Coronavirus recover faster, it does not significantly reduce death, according to preliminary data from the National Institutes of Health.


“The data shows that Remdesivir has a clear cut, significant, positive effect in diminishing, the time of recovery,” the director of the National Institute of Allergy and Infectious Diseases, Dr Anthony Fauci said during a meeting between president Trump and Louisiana Governor John Bel Edwards.


Below is a video of Dr Babafemi Taiwo speaking to CNN about the promising results of Remdesivir in treating COVID-19.

Clinical Trials Arena is using cookies.

We use them to give you the best experience. If you continue using our website, we’ll assume that you are happy to receive all cookies on this website.

A number of drugs are being developed and tested for the treatment of the novel coronavirus. Coronavirus: timeline of events and latest updates.

The mysterious coronavirus outbreak in the Chinese city Wuhan, now termed as COVID-19, and its fast spread to many other countries, endangers thousands of lives.

The pandemic has catalysed the development of novel coronavirus vaccines across the biotech industry, both by pharmaceutical companies and research organisations such as the National Institutes of Health (NIH), US.

The first COVID-19 vaccine in China is expected to be ready for clinical trials by the end of April, according to Xu Nanping, China’s vice-minister of science and technology.

Inovio Pharmaceuticals plans to begin clinical trials on a coronavirus vaccine in April this year.

Health officials from WHO have noted that Gilead’s remdesivir has demonstrated efficacy in treating the coronavirus infection. Chloroquine approved for emergency use by US FDA.

The US Food and Drug Administration (FDA) approved limited emergency use for chloroquine and hydroxychloroquine as a treatment for COVID-19.

The President of the United States, Donald Trump, had announced on 19 March that chloroquine and hydroxychloroquine/Plaquenil, used to treat malaria and arthritis, were approved by the FDA to be tested as a treatment for COVID-19.

Chloroquine is being tested in various clinical trials conducted by government agencies and academic institutions.

Other antivirals drugs are also planned to be fast-tracked for testing for coronavirus. Favilavir, the first approved coronavirus drug in China.

The National Medical Products Administration of China has approved the use of Favilavir, an anti-viral drug, as a treatment for coronavirus.

The drug has reportedly shown efficacy in treating the disease with minimal side effects in a clinical trial involving 70 patients.

The clinical trial is being conducted in Shenzhen, Guangdong province.

Pharmaceutical companies involved in developing coronavirus drugs/vaccines.

Here is a list of the major coronavirus drugs that pharmaceutical companies across the world are developing that have the potential to become major coronavirus vaccines or antivirals for treating the contagious coronavirus infection.

Novel coronavirus vaccines. Fusogenix DNA vaccine by Entos Pharmaceuticals. Entos Pharmaceuticals is developing Fusogenix DNA vaccine developed using the Fusogenix drug delivery platform to prevent COVID-19 infections.

Fusogenix drug delivery platform is a proteo-lipid vehicle that introduces genetic payload directly into the cells.

Entos is working on developing an optimised payload containing multiple protein epitopes derived from SARS-COV-2 proteins, which will stimulate an immune response in the body to prevent COVID-19 infection.

ChAdOx1 nCoV-19 by University of Oxford. The University of Oxford’s ChAdOx1 nCoV-19 is an adenovirus vaccine vector developed by the university’s Jenner Institute.

The university is testing the vaccine in a clinical trial planned to be conducted in the Thames Valley Region.

Gimsilumab by Roivant Sciences. Roivant Sciences is advancing the development of Gimsilumab a clinical-stage, human monoclonal antibody.

The drug targets granulocyte-macrophage colony stimulating factor (GM-CSF), which is a pro-inflammatory cytokine found in high levels in the serum of COVID-19 patients. AdCOVID by Altimmune. Altimmune has collaborated with the University of Alabama at Birmingham (UAB) to develop a single dose intranasal vaccine for COVID-19 named AdCOVID.

The company is currently carrying out immunogenicity studies after, which phase one clinical trial material will be developed. Altimmune and UAB will work with researchers to conduct preclinical animal studies and phase one clinical trial in the third quarter of 2020.

TJM2 by I-Mab Biopharma. I-Mab Biopharma is developed TJM2, a neutralising antibody, as a treatment for cytokine storm in patients suffering from a severe case of coronavirus infection. The drug targets the human granulocyte-macrophage colony-stimulating factor (GM-CSF), which is responsible for acute and chronic inflammation.

The company will commence development after receiving approval for the Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA). Coronavirus vaccine by Medicago.

Medicago is developing drug candidates against COVID-19 after having produced Virus-Like Particles (VLP) of the coronavirus.

The company has formed a collaboration with Laval University’s Infectious Disease Research Centre to develop antibodies against SARS-CoV-2. AT-100 by Airway Therapeutics. Airway Therapeutics is exploring its novel human recombinant protein named AT-100 (rhSP-D) as a treatment for coronavirus. The company has announced a filing with the Respiratory Diseases Branch of the National Institutes of Health to evaluate the drug.

AT-100 has shown efficacy in preclinical studies in reducing inflammation and infection in the lungs, while also generating an immune response against various respiratory diseases. TZLS-501 by Tiziana Life Sciences. Tiziana Life Sciences is developing its monoclonal antibody named TZLS-501 for the treatment of COVID-19. TZLS-501 is a human anti-interleukin-6 receptor (IL-6R), which helps in preventing lung damage and elevated levels of IL-6.

The drug works by binding to IL-6R and depleting the amount of IL-6 circulating in the body thereby reducing chronic lung inflammation. OYA1 by OyaGen.

OyaGen’s OYA1 has shown strong antiviral efficacy against coronavirus in laboratory essays. It was found to be more effective than chlorpromazine HCl in inhibiting SARS-CoV-2 from replicating in cell culture. OYA1 was earlier approved as an investigational new drug for treating cancer but abandoned due to lack of efficacy.

OyaGen plans to conduct further research on the drug to determine the efficacy in treating coronavirus. BPI-002 by BeyondSpring . BeyondSpring’s BPI-002 is a small molecule agent indicated for treating various infections including COVID-19.

It has the ability to activate CD4+ helper T cells and CD8+ cytotoxic T cells and generating an immune response in the body. If combined with another COVID-19 vaccine, the drug has the ability to generate long-term protection against viral infections.

BeyondSpring has filed US patent protection for the drug for treating viral infections. Altimmune’s intranasal coronavirus vaccine. An intranasal Covid-19 vaccine is being developed by US-based clinical-stage biopharmaceutical company, Altimmune.

Design and synthesis of the single-dose vaccine have been completed, while animal testing will follow.

The coronavirus vaccine is being developed based on a vaccine technology platform that is similar to NasoVAX, an influenza vaccine developed by Altimmune. INO-4800 by Inovio Pharmaceuticals and Beijing Advaccine Biotechnology. Inovio Pharmaceuticals has collaborated with Beijing Advaccine Biotechnology Company to advance the development of the former’s vaccine, INO-4800, as a novel coronavirus vaccine. The company has started pre-clinical testing for clinical product manufacturing.

The vaccine development is supported by a $9m grant from the Coalition for Epidemic Preparedness Innovations (CEPI).

Inovio announced an accelerated timeline for the development of the vaccine on 03 March. Preclinical trials are ongoing and the design for human clinical trials have been completed.

The company has also prepared 3,000 doses for human clinical trials planned to be conducted across the US, China, and South Korea.  Plans for large-scale manufacturing have also been developed.

Human clinical trials in 30 healthy volunteers are expected to commence in April 2020 in the US, followed by China, and South Korea. A phase one clinical trial is planned to be conducted in parallel in China, by Beijing

Results from the clinical trials are expected to be available in September 2020. Inovio aims to produce one million doses of the vaccine by the end of 2020 to perform additional clinical trials or emergency use. NP-120 (Ifenprodil) by Algernon Pharmaceuticals. Algernon Pharmaceuticals has announced that it is exploring its NP-120 (Ifenprodil) as a potential treatment COVID-19. Ifenprodil is an N-methyl-d-aspartate (NDMA) receptor glutamate receptor antagonist sold under the brand name Cerocal. It has demonstrated efficacy in improving survivability in mice infected with H5N1. APN01 by University of British Columbia and APEIRON Biologics. A drug candidate developed by APEIRON Biologics named APN01 is being tested in China in a phase one pilot trial as a treatment for COVID-19. APN01 is based on research conducted by a professor at the University of British Columbia for treating SARS. The research revealed that the ACE2 protein was the main receptor for the SARS virus. The clinical trial will test the drug’s efficacy in reducing the viral load in patients. Data from the trial will be used to determine if additional clinical trials are required to be conducted in larger number of patients. mRNA-1273 vaccine by Moderna and Vaccine Research Center. Moderna and the Vaccine Research Center, a unit of the National Institute of Allergy and Infectious Diseases (NIAID), have collaborated to develop a vaccine for coronavirus. The vaccine targets the Spike (S) protein of the coronavirus. The first vials of the vaccine have been manufactured at Moderna’s Massachusetts manufacturing plant and shipped to NIAID for phase one human clinical trial. The trial began on 16 March at the Kaiser Permanente Washington Health Research Institute in Seattle, Washington. A total of 45 males and females aged between 18 and 45 have been enrolled for the trial. The participants will be divided into three cohorts who will be administered 25 microgram (mcg), 100mcg or 250mcg dose 28 days apart. Avian Coronavirus Infectious Bronchitis Virus (IBV) vaccine by MIGAL Research Institute. The MIGAL Research Institute in Israel announced that an Infectious Bronchitis Virus (IBV) vaccine developed to treat avian coronavirus has been modified to treat COVID-19. The vaccine has demonstrated efficacy in pre-clinical trials conducted by the Volcani Institute. The IBV vaccine was developed after four years of research and has high genetic similarity to the human coronavirus. The institute has genetically modified the vaccine to treat COVID-19 and will be available in the oral form. The institute is currently exploring potential partners for producing the vaccine in the next eight to ten weeks and obtaining the necessary safety approvals for in-vivo testing. TNX-1800 by Tonix Pharmaceuticals. Tonix Pharmaceuticals has partnered with Southern Research, a non-profit research organisation, to develop a vaccine for coronavirus named TNX-1800.  The vaccine is a modified horsepox virus developed using Tonix’s proprietary horsepox vaccine platform. TNX-1800 is designed to express a protein derived from the virus that causes the coronavirus infection. Southern Research will be responsible for evaluating the efficacy of the vaccine, under the partnership. Brilacidin by Innovation Pharmaceuticals. Innovation Pharmaceuticals announced that it is evaluating Brilacidin, a defensin mimetic drug candidate, as a potential treatment for coronavirus. Brilacidin has shown antibacterial, anti-inflammatory and immunomodulatory properties in several clinical trials. The company is planning to explore research collaborations and seek federal grants to develop the coronavirus drug. It is already investigating the drug for inflammatory bowel disease and oral mucositis in cancer patients. Innovation has signed two material transfer agreements with a university in the US and 12 biocontainment labs in the US for evaluation of Brilacidin as a treatment for COVID-19. One of the biocontainment labs is scheduled to commence testing of the drug in the third week of March. Recombinant subunit vaccine by Clover Biopharmaceuticals. Clover Biopharmaceuticals is developing a recombinant subunit vaccine using its patented Trimer-Tag© technology. The company is developing the vaccine based on the trimeric S protein (S-Trimer) of the COVID-19 coronavirus, which is responsible for binding with the host cell and causing a viral infection. Using Trimer-Tag© technology, Clover successfully produced the subunit vaccine in a mammalian cell-culture based expression system on 10 February. The company also identified antigen-specific antibody in the serum of fully recovered patients who were previously infected by the virus. A highly purified form of the S-Trimer vaccine is expected to be available in six to eight weeks for performing pre-clinical studies. The company is equipped with in-house cGMP biomanufacturing capabilities to scale-up production if the vaccine is proven to be successful. Vaxart’s coronavirus vaccine. Vaxart is developing an oral recombinant vaccine in tablet formulation using its proprietary oral vaccine platform, VAAST. The company plans to develop vaccines based on the published genome of 2019-nCOV to be tested in pre-clinical models for mucosal and systemic immune responses. CytoDyn-leronlimab . CytoDyn is examining leronlimab (PRO 140), a CCR5 antagonist, as a potential coronavirus drug. The drug is already being investigated in phase two clinical trials as a treatment for HIV and has been awarded fast-track approval status by the United States Food and Drug Administration. Linear DNA Vaccine by Applied DNA Sciences and Takis Biotech. Applied DNA Sciences’ subsidiary LineaRx and Takis Biotech formed a joint venture on 07 February to develop a linear DNA vaccine as a treatment for coronavirus. The JV will use Polymerase Chain Reaction (PCR)-based DNA manufacturing technology to develop the vaccine. The PCR technology offers several advantages including high purity, increased production speed, and absence of antibiotics and bacterial contaminants. Further, the vaccine gene developed through this technology can be effective without being inserted into the patient’s genome. The design for four DNA vaccine candidates is expected to be produced using the PCR technology for carrying out animal testing. The design of one of the vaccine candidates is based on the entire spike gene of the coronavirus, while the remaining are designed based on the antigenic portions of the protein. BXT-25 by BIOXYTRAN to treat late-stage acute respiratory distress syndrome (ARDS). BIOXYTRAN announced that it is exploring partners to develop its lead drug candidate, BX-25, as a treatment for Acute Respiratory Distress Syndrome (ARDS) in late-stage patients infected with the coronavirus. The diffusion of oxygen to the blood is comprised in patients suffering from ARDS leading to fluid build-up in the lungs. BX-25 is designed to be 5,000 times smaller than blood cells and efficiently transport oxygen through the body for a period of nine hours before being processed by the liver. The drug can help in supplying oxygen to the vital organs and enable the patient to recover and survive. Novavax’s MERS coronavirus vaccine candidate. Novavax developed a novel Middle East Respiratory Syndrome (MERS) coronavirus vaccine candidate in 2013, post the identification of the first MERS coronavirus ((MERS-CoV) in Saudi Arabia in 2012. It is a crucial target for vaccine development by the Coalition for Epidemic Preparedness Innovations (CEPI) and is a priority disease for the World Health Organisation (WHO). The candidate is designed to primarily bind to the major surface S-protein and developed using the company’s recombinant nanoparticle vaccine technology. Tested along with the Novavax’s proprietary adjuvant Matrix-M™, it inhibited infection by inducing immune responses in the laboratory studies. Novavax has received $4m in funding from CEPI to advance the development of the vaccine. The company has produced several nanoparticle vaccine candidates for testing in animal models and aims to carry out human trials in 2020. The MERS coronavirus is related to the severe acute respiratory syndrome (SARS) coronavirus, for which the company had previously developed a recombinant nanoparticle vaccine candidate. Inovio Pharma’s INO-4700. The investigational DNA immunotherapy, INO-4700 (GLS-5300) is being developed by Inovio in partnership with GeneOne Life Science. It is delivered as vaccine intramuscularly, using the Cellectra® delivery device. The company has received a $5m grant from the Bill and Mellinda Gates foundation to accelerate the development of the Cellectra® delivery device. The vaccine was well-tolerated and demonstrated high immune responses against the MERS-CoV in 94% of patients in the early-stage clinical trial in July 2019. It also generated broad-based T cell responses in 88% of the subjects. Coronavirus drugs. Remdesivir (GS-5734) by Gilead Sciences. An ebola drug developed by Gilead Sciences that was found to be ineffective is now being tested in two phase III randomised clinical trials in Asian countries. The trials are being performed on 761 patients in a randomised, placebo-controlled, double-blind study at multiple hospitals in Wuhan, the epicentre of the novel coronavirus outbreak. The results from the trials are expected to be available over the next few weeks. According to a report by The New England Journal of Medicine (NEJM), remdesivir, when administered to a coronavirus patient in the US, appeared to have improved the clinical condition. The University of Nebraska Medical Center is also carrying out clinical trials to test the safety and efficacy of the drug. The first patient to be administered the drug is an evacuee from the Diamond Princess cruise ship. Actemra by Roche to treat coronavirus-related complications. China approved the use of Roche’s Actemra for the treatment of severe complications related to coronavirus. Drugs like Actemra have the ability to prevent cytokine storms or overreaction of the immune system, which is considered as the main reason behind organ failure leading to death in some coronavirus patients. Actemra is also being evaluated in a clinical trial in China, which is expected to enroll 188 coronavirus patients. The clinical trial is expected to be conducted until May 10. Biocryst Pharma’s Galidesivir, a potential antiviral  for coronavirus treatment. The antiviral drug Galidesivir (BCX4430) has shown broad-spectrum activity against a wide range of pathogens including coronavirus. It is a nucleoside RNA polymerase inhibitor that disrupts the process of viral replication. The drug has already shown survival benefits in patients against deadly viruses such as Ebola, Zika, Marburg, and Yellow fever. Galidesivir is currently in advanced development stage under the Animal Rule to combat multiple potential viral threats including coronaviruses, flaviviruses filoviruses, paramyxoviruses, togaviruses, bunyaviruses, and arenaviruses. Regeneron’s REGN3048-3051 and Kevzara. Discovered by Regeneron, the combination of neutralising monoclonal antibodies REGN3048 and REGN3051 is being studied against coronavirus infection in a first-in-human clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID). The safety and tolerability of the drug will be studied in 48 patients. Both the antibodies bind to S-protein of MERS coronavirus. The intravenous administration of the drug in the mouse model of MERS resulted in the high-level neutralisation of the MERS coronavirus in circulating blood with reduced viral loads in the lungs. Regeneron has partnered with Sanofi to evaluated Kevzara, a fully-human monoclonal antibody, in a phase two/three clinical trial in patients with severe COVID-19 infection. Kevzara is approved for the treatment of rheumatoid arthritis and is known to block the interleukin-6 (IL-6) pathway, which causes an overactive inflammatory response in the lungs of COVID-19 patients. SNG001 by Synairgen Research. Synairgen Research’s SNG001, an inhaled drug, is planned to be tested by the University of Southampton to treat asthma, chronic obstructive pulmonary disease and lower respiratory tract illnesses caused by coronavirus. SNG001 is a formulation of naturally occurring Interferon-β, which is administered through a nebuliser and is delivered directly to the lungs to reduce the severity of the infection caused by coronavirus. AmnioBoost by Lattice Biologics. Lattice Biologics is exploring the efficacy of its amniotic fluid concentrate, AmnioBoost, in treating acute respiratory distress syndrome (ARDS) in COVID-19 patients. AmnioBoost was developed for chronic adult inflammatory conditions such as osteoarthritis. The drug has shown efficacy in reducing the inflammatory conditions caused by several diseases including coronavirus. It reduces the production of pro-inflammatory cytokines while boosting the production of anti-inflammatory cytokines. Companies such as Inovio Pharmaceuticals, Moderna, and Novavax have been reported to be developing vaccines. A total of 30 therapies are being tested, including few traditional medicines for coronavirus treatment by Chinese scientists. Chloroquine phosphate has shown efficacy in treating symptoms of the disease, among the 30 therapies. Patients administered with the drug achieved a better drop in fever and shorter recovery time in clinical trials being conducted in hospitals in the Guangdong province and Hunan province. Enanta Pharmaceuticals has announced its plans to develop antiviral drug candidates to treat COVID-19 patients. The company is testing compounds from its existing antiviral compound library for potential efficacy in treating COVID-19. It has also launched a drug discovery programme to develop direct-acting drug candidates to treat COVID-19. Predictive Oncology. Predictive Oncology has launched an AI Platform for the discovery and development of vaccines against coronavirus. The company has signed an agreement with InventaBioTech to acquire Soluble Therapeutics, which provides it with access to the HSCTM Technology. Predictive will use the HSCTM Technology along with its predictive modeling platform to deploy an AI discovery platform that can screen the ideal combination of additives and excipients for protein formulations. Emergent BioSolutions. Emergent BioSolutions is developing two plasma-derived product candidates or hyperimmunes using its hyperimmune platforms for the treatment of coronavirus. The hyperimmune platforms have been used previously for the development of several approved products including vaccines for smallpox, botulism, and anthrax. The hyperimmunes are polyclonal antibodies derived from plasma, which are capable of generating an immune response and protecting against infection. Product candidate derived from human plasma is named COVID-HIG, while COVID-EIG is derived from equine plasma. Both will be explored for the treatment of patients with a severe case of infection. Integral Molecular. Integral Molecular has launched a vaccine programme using its two technology platforms including Shotgun Mutagenesis Epitope Mapping and the Membrane Proteome Array. The technologies will help in understanding the human immune response to the coronavirus and isolate the cellular receptors that enable the virus to spread quickly. The Shotgun technology helps in identifying more than 1,000 binding sites for antibodies, while the Membrane Proteome Array technology is capable of identifying the receptors through which viruses infect cells. CEL-SCI. CEL-SCI is developing immunotherapy against COVID-19 using its proprietary LEAPS peptide technology, which utilises conserved areas of the coronavirus proteins to generate T-cell responses and reduce viral load. The technology can also be used to develop immunotherapeutic peptides with both antiviral and anti-inflammatory properties. The peptides developed using this technology can help in reducing tissue damage from inflammation caused due to lung infection, which is a major cause of mortality in elderly patients. AJ Vaccines. AJ Vaccines has launched the development of a vaccine against COVID-19. The company will use the latest technology to develop antigens that can mimic the native structures of the virus. The vaccine will be capable of inducing a strong immune response in the body thereby protecting against the infection. Takeda Pharmaceutical Company. Takeda Pharmaceutical Company has announced plans to develop a plasma-derived therapy against coronavirus. The anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) therapy will be designed to treat high-risk patients. The H-IG therapy includes concentrated pathogen-specific antibodies derived from plasma of recovered patients. These antibodies have the potential to generate an immune response when injected into a new patient. Heat Biologics. Heat Biologics has announced plans to develop a vaccine to treat or prevent coronavirus infection using its proprietary gp96 vaccine platform. The technology is capable of reprogramming live cells to produce antigens that can bind to the gp96 protein and generate an immune response against those antigens. Pfizer. Pfizer announced that it has identified certain under development antiviral compounds that may be effective in treating coronavirus. The company is planning to partner with a third party to screen and identify potential compounds by the end of March and begin testing in April. Mateon Therapeutics. Mateon Therapeutics has launched an antiviral response programme to develop coronavirus treatments using its therapeutic and artificial intelligence (AI) platforms. It has also established a division, which will adopt a multi-modal approach to developing COVID-19 treatments as well as other future zootonic outbreaks. Hong Kong University of Science and Technology. The Hong Kong University of Science and Technology has identified several vaccine targets, which can be developed as a treatment for coronavirus. Researchers at the university have identified B-cell and T-cell epitopes, which are capable of generating an immune response against the SARS virus and a similar response against the coronavirus. Vaccine by Generex. Generex has announced that it is developing a COVID-19 vaccine following a contract from a Chinese consortium comprising of China Technology Exchange, Beijing Zhonghua Investment Fund Management, Biology Institute of Shandong Academy of Sciences and Sinotek-Advocates International Industry Development. The company will utilise its Ii-Key immune system activation technology to produce a COVID-19 peptide for human clinical trials. Generex will receive an upfront payment of $1m to commence the groundwork for the vaccine development and $5m licensing fee for its Ii-Key technology. It is also eligible to receive a 20% royalty on every dose of vaccine produced under the contract. Coronavirus drugs by Columbia University. Researchers at Columbia University have been awarded a $2.1m grant by the Jack Ma Foundation to develop a coronavirus cure. Four different teams at the university will adopt various approaches towards the development of a vaccine against coronavirus. Vaccine by Tulane University. Tulane University has launched a research programme to identify a potential coronavirus medicine in the form of a vaccine. The university will utilise a grant from the Brown Foundation to carry out the research activities. Coronavirus vaccine by ImmunoPrecise Antibodies . ImmunoPrecise Antibodies has launched a vaccine and therapeutic antibody programme to develop a vaccine as well as antibodies against COVID-19. The company will use its B Cell Select™ and DeepDisplay™ discovery platforms to therapeutic compounds against the coronavirus. The company has updated its research efforts and noted that it will be using the PolyTope mAb TherapyTM and EVQLV’s artificial intelligence platforms develop a COVID-19 therapy. Serum Institute of India. Serum Institute of India (SII) is collaborating with Codagenix, a US-based biopharmaceutical company, to develop a cure for coronavirus using a vaccine strain similar to the original virus. The vaccine is currently in the pre-clinical testing phase, while human trials are expected to commence in the next six months. SII is expected to launch the vaccine in the market by early 2022. Southwest Research Institute. Southwest Research Institute is using its virtual screening called Rhodium to identify potential drug candidates for treating coronavirus from more than two million drug compounds. The most promising compounds will be identified for further development. Zydus Cadila. Zydus Cadila announced the launch of an accelerated research programme to develop a vaccine for COVID-19 using two novel approaches. The first approach includes the development of a DNA vaccine against the viral membrane protein of the virus, while a live attenuated recombinant measles virus (rMV) vectored vaccine will be developed in the second approach. The rMV-based vaccine works by inducing specific neutralising antibodies, which will provide protection from the coronavirus infection. NanoViricides. NanoViricides, a clinical-stage company, is working on developing a treatment for nCoV-2019 using its nanoviricide® technology. The company’s technology is used to develop ligands that can bind to the virus in the same way as a cognate receptor and attack various points of the virus. Vir Biotechnology. Vir Biotechnology, a clinical-stage immunology company, announced on 12 February that it has identified two monoclonal antibodies that can bind to the virus that causes COVID-19. The antibodies target the spike (S) protein of the virus by entering through the cellular receptor ACE2. The company has formed a partnership with WuXi Biologics on 25 February to commercialise the antibodies identified to treat coronavirus. If approved, Wuxi will have the rights to market the therapies in China, while Vir will retain the marketing rights in other countries. Vir has also partnered with Alnylam Pharmaceuticals to identify siRNA candidates targeting SARS-CoV-2. It has formed another partnership with Biogen for cell line and process development and manufacturing of the antibodies. HIV drugs for coronavirus treatment. Abbvie’s HIV protease inhibitor, lopinavir is being studied along with ritonavir for the treatment of MERS and SARS coronaviruses. The repurposed drug is already approved for the treatment of HIV infection under the trade name Kaletra®. The combination is listed in the WHO list of essential medicines. Lopinavir is believed to act on the intracellular processes of coronavirus replication and demonstrated reduced mortality in the non-human primates (NHP) model of the MERS.

Lopinavir/ritonavir in combination with ribavirin showed reduced fatality rate and milder disease course during an open clinical trial in patients in the 2003 SARS outbreak.

Cipla is also reportedly planning to repurpose its HIV drug LOPIMUNE, which is a combination of protease inhibitors Lopinavir and Ritonavir, for the treatment of coronavirus.

A licensed generic of Kaletra®, LOPIMUNE is currently available in packs of 60 tablets each, containing 200mg of Lopinavir and 50mg of Ritonavir. Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson, donated its PREZCOBIX® HIV medication (darunavir/cobicistat) for use in research activities aimed at finding a treatment for COVID-19. Darunavir is a protease inhibitor marketed by Janssen.

Anecdotal reports suggest darunavir as potentially having antiviral activity against COVID-19.

It is, however, currently approved only for use with a boosting agent, and in combination with other antiretrovirals, for the treatment of HIV-1. Janssen has no in vitro or clinical data to support the use of darunavir as a treatment for  COVID-19.

The drug is in the process of being evaluated in vitro for any potential activity against the coronavirus. Further, Janssen has partnered with the Biomedical Advanced Research and Development Authority (BARDA) to expedite the development of a COVID-19 treatment. The Coronavirus outbreak.

The contagious coronavirus outbreak at the end of 2019, which the WHO named as COVID-19 (formerly 2019-nCoV), led to a medical emergency across the world. What are the symptoms? Coronavirus transmission.

“Coronavirus transmission can happen human-to-human as well as from infected animals such as dogs and cats.“. COVID-19 is a betacoronavirus that has origin in bats, according to the Centers for Disease Control and Prevention (CDC).

Believed to have transmitted from animals and reptiles such as snakes, coronaviruses cause respiratory issues such as upper respiratory tract illnesses and lower respiratory illnesses such as pneumonia and bronchitis.

CSM, a Clinigen company. VaLea Clinical Trials specialises in providing convenient patient-centric services for clinical trials in the home or alternate-site settings, based in Vienna, Austria. VaLea Clinical Trials. VaLea Clinical Trials specialises in providing convenient patient-centric services for clinical trials in the home or alternate-site settings, based in Vienna, Austria.

SOM Biotech is an Artificial Intelligence AI drug discovery and development company focused on the development of therapies for orphan indications through the proprietary AI-based drug discovery technology. Programme SOM0044 for Parkinson’s Disease.

Programme  SOM0208 for the Treatment of Niemann–Pick Type C Disease. SOM Biotech. SOM Biotech is an Artificial Intelligence AI drug discovery and development company focused on the development of therapies for orphan indications through the proprietary AI-based drug discovery technology. Coronavirus outbreak: The countries affected.


49 patients who suffered from corona-virus have been discharged in Lagos

49 discharged patients

49 COVID-19 patients have been discharged in Lagos today April 29.


According to the Lagos state Ministry of Health, out of the 49 discharged patients, 28 of them were females and 21 of them were males including a Greek national.

49 patients who suffered from corona-virus have been discharged in Lagos


The patients were discharged from Isolation facilities at Yaba and Onikan.


49 COVID-19 patients discharged in Lagos

Source: Lindaikaji


In China Students wear social distancing headgears to class as schools resume(Photo)

Students wear social distancing headgears to class as schools resume in China (photos)

Students wear social distancing headgears to class as schools resume in China (photos)

Life in China is now returning to normalcy since the outbreak of Coronavirus.


With some schools slowly reopening after the long hiatus, one school in the city of Hangzhou have enforced social distancing by letting students wear DIY hats with 3-foot-long horizontal plumes.
Duke University professor, Eileen Chengyin Chow shared photos showing first graders at the Yangzheng Elementary School sitting in a classroom with desks arranged in single rows.


Students wear social distancing headgears to class as schools resume in China (photos)


In the pictures, the students were also pictured wearing face masks and colourful headgear with extended plumes made out of cardboard and, in one case, balloons.

According to Chinese outlet, The Paper, students at the school are allowed to wear the headgear to remind them to keep their distance from each other.
This comes a day after the Hubei province health commission announced that Wuhan, the city at the center of China’s coronavirus outbreak, has no more hospitalized patients after the last 12 were discharged on Sunday.


Update-Cuban doctors arrive South Africa to help the country fight Coronavirus

Cuban doctors arrive South Africa to help the country fight Coronavirus

Cuban doctors arrive South Africa to help the country fight Coronavirus

More than 200 doctors from Cuba have arrived in South Africa to help fight the COVID-19 pandemic.


The doctors, including community health and infectious disease specialists, arrived early Monday morning, April 27, and were welcomed by military and health authorities.


Overwhelmed with the increasing cases of Coronavirus, South Africa requested assistance from the Cuban government, which is sending more than 1,000 doctors to 22 countries, including Togo, Cape Verde and Angola in Africa.


Cuban doctors arrive South Africa to help the country fight Coronavirus


South Africa has reported the highest number of confirmed COVID-19 infections in Africa, with at least 4,546 cases and 87 deaths.


Some of the Cuban doctors have been “in the frontline of fighting other outbreaks in the world such as cholera in Haiti in 2010, and Ebola in West Africa in 2013,” said South African health minister Zweli Mkhize.


The Cuban doctors who arrived in South Africa will be in qarantine for two weeks before starting work.


Rising deaths in Kano caused by Malaria, other illnesses- Muhammad Garba

Rising deaths in Kano caused by Malaria, other illnesses – State Commissioner for Information says

Rising deaths in Kano caused by Malaria, other illnesses - State Commissioner for Information says

The Commissioner for Information in Kano state, Muhammad Garba, has said preliminary investigation shows the rising cases of death recorded in the state, is majorly caused by ”complications arising from hypertension, diabetes, meningitis and acute malaria”.


Garba disclosed this in a statement. Part of the statement reads

Although an investigation into the cause of the deaths is still ongoing, preliminary reports from the state Ministry of Health indicated that the deaths are not connected to the COVID-19 pandemic. Reports have shown that most of the deaths were caused by complications arising from hypertension, diabetes, meningitis, and acute malaria.

Moreso, the state government has three modern Isolation Centres where those tested positive to COVID-19 are being cared for. We are also hopeful of getting an additional two Isolation Centres soonest. The government has also hired a hotel where suspected cases are accommodated.

Also, the Kano State Government is collaborating with? Bayero University Kano to establish a testing centre within the institution, which will be ready in two weeks time after being certified by the NCDC. This will, indeed, enhance our determination to ensure that every suspected case undergo a test.”


Update- Three patients in Kano flee after testing positive for Coronavirus

Three patients in Kano flee after testing positive for Coronavirus

Three patients in Kano flee after testing positive for Coronavirus

Three persons who tested positive for Coronavirus in Kano state, have reportedly fled from their known addresses.


Kano State coordinator of technical response team on COVID-19, Tijjani Hussaini told Premium Times that his team is working with security agencies to trace the patients who fled their places of residence and switched off their phones.


When apprehended, the patients will be moved to the designated isolation centre. Hussaini said;


“Out of 77 confirmed cases tested positive in Kano, we are yet to trace three persons, because they have changed (their) place(s) of residence and switched off their phones. But we have sought the assistance of security personnel to trace them and take appropriate action.”


The  Kano official also disclosed that 73 persons are currently receiving treatment at the state’s isolation centres.


NHS issues urgent alert as children are being admitted to intensive care

NHS issues urgent alert as children are being admitted to intensive care with a new Coronavirus-related ‘inflammatory syndrome’ (photo)


NHS issues urgent alert as children are being admitted to intensive care with a new Coronavirus-related

The National Health Service (NHS) has been issued an urgent alert about a spike in the number of children being admitted to intensive care with a Coronavirus-related condition.


In an alert sent to GPs, health chiefs said: ‘There is growing concern that a [COVID-19] related inflammatory syndrome is emerging in children in the UK.


‘Over the last three weeks, there has been an apparent rise in the number of children of all ages presenting with a multi-system inflammatory state requiring intensive care across London and also in other regions of the UK.’


According to NHS doctors, the children who are seen with the [COVID-19] related inflammatory syndrome are commonly suffering from stomach pain and ‘gastrointestinal symptoms’ – which could include vomiting and diarrhoea.

The doctors said they have compared the mysterious condition to toxic shock syndrome and Kawasaki disease which can cause redness of the tongue and rashes, but it is unclear whether this illness is having those effects.


But some of the children presenting with the illness have tested negative for the Coronavirus, further complicating the diagnosis,  the Health Service Journal reported.

The memo, which was sent out by an NHS trust in London and tweeted by the Paediatric Intensive Care Society, said: ‘The cases have in common overlapping features of toxic shock syndrome and atypical Kawasaki disease with blood parameters consistent with severe COVID-19 in children.’


NHS issues urgent alert as children are being admitted to intensive care with a new Coronavirus-related


The alert told GPs to refer children with symptoms including abdominal pain as a ‘matter of urgency’.


According to the NHS memo, cases of this inflammatory syndrome have only started to appear in the past three weeks – this may be because it is slow to develop or so rare that it has only become noticeable in the peak of the UK’s epidemic, when around a million people are believed to have been infected in London alone.


A paediatrician at St Mary’s Hospital in the capital, Dr Elizabeth Whittaker, said on Twitter that medics in other countries had reported the same illness.


Dr. Whittaker said: ‘Our Italian and Spanish colleagues also report it. Numbers are small but significant. We want primary care /A&E to be vigilant so those affected are in the right place to get appropriate supportive care if needed.’

Only nine people under the age of 19 have died in England from Coronavirus, out of a total of 18,420 reported by yesterday, April 26.


Australians Rush To Download Coronavirus Tracing App, PM’s Popularity Soars

More than a million Australians rushed to download an app designed to help medical workers and state governments trace close contacts of COVID-19 patients, as Prime Minister Scott Morrison’s approval rating soared on his pandemic response.

Australia has been one of the most successful countries in fighting the coronavirus pandemic, recording just 83 deaths and 6,700 cases, because of border closures, movement restrictions and a stay-at-home policy. It has lowered the daily growth in new infections to less than 1%, well down from the 25% seen in March.

Australia has indicated it might lift some of the social distancing restrictions starting May 11. Morrison has said at least 40% of the population will need download the app, which allows health authorities to trace users’ movements.

Despite privacy concerns, Health Minister Greg Hunt said 1.13 million Australians downloaded the tracing app CovidSafe as of 6 a.m. (2000 GMT) on Monday, nearly 4.5% of the country’s population.

The first one million downloads came within five hours of launching the app, he added.

When asked how many people need to download the app for it to be successful, Hunt said “there is no magic number.”

“As many as possible is our real goal,” he added. “It is about assisting our disease experts find people who might have been exposed and we are well ahead of our best hopes and expectations already.”

Australia’s chief medical officer, Brendan Murphy, said the downloads would help contain the spread of the virus.

Canberra will soon begin testing people regardless of symptoms, he said, adding that it would focus on young adults.

The surge in downloads comes as a Newspoll conducted for The Australian newspaper showed Morrison enjoyed the best approval rating for a leader since the end of 2008.

Morrison’s approval rating has skyrocketed 27 points since the first week of March to 68%, the poll showed.

The result was boosted as Morrison jettisoned much of his conservative government’s ideology to pledge spending worth more than 10% of GDP, including a A$130 billion ($83.82 billion) subsidy to employers to keep staff they might otherwise have let go.

Westpac chief economist Bill Evans estimates that without the subsidy unemployment would have soared to 17% by the end of June, but would now only reach 9%.

Business groups in the country have begun lobbying for easing pandemic-related restrictions.

A modelling by the Business Council of Australia on Monday showed the A$2 trillion economy could take a A$400 billion hit if restrictions adopted to fight the spread of Covid-19 continued for six months.

Last week, the head of Australia’s central bank said the country would suffer its biggest economic contraction since the 1930s in the first half of this year due to the containment measures.

He estimated national output would fall by around 10% in the first half of 2020 with unemployment almost doubling to around 10% by June.

Despite the economic pain, Australia reported just five new cases of coronavirus across the country in the last 24 hours. Australia’s most populous state, New South Wales, said it had found just two cases in that time, and neither involved community transmission.

The states of Queensland and Western Australia have said they would ease some restrictions this week, as both have had new cases in the low single digits in recent days.

Western Australia will allow indoor and outdoor gatherings of up to 10 people, while Queensland has allowed picnics, retail shopping and drives of up to 50 kms (31 miles) from home. Queensland has also opened its national parks.

The most populous states of Victoria and New South Wales, which have the country’s coronavirus hotspots, are maintaining strict social and business restrictions.